The volatility ratio for the week is 15.87%, and the volatility levels for the past 30 days are at 13.97% for AARD. The simple moving average for the past 20 days is -9.65% for AARD’s stock, with a -13.97% simple moving average for the past 200 days.
Is It Worth Investing in Aardvark Therapeutics Inc (NASDAQ: AARD) Right Now?
Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AARD is 12.39M, and currently, short sellers hold a 2.58% ratio of that float. The average trading volume of AARD on May 15, 2025 was 121.22K shares.
AARD) stock’s latest price update
The stock price of Aardvark Therapeutics Inc (NASDAQ: AARD) has dropped by -13.81 compared to previous close of 10.14. Despite this, the company has seen a fall of -17.78% in its stock price over the last five trading days. globenewswire.com reported 2025-05-14 that Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early 2026 $151.3 million in cash, cash equivalents, and short-term investments supports projected operations into 2027 SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) — Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended March 31, 2025, and provided business highlights. “We believe that there is a significant, untapped opportunity to target anti-hunger signaling to treat rare metabolic diseases and obesity.
Analysts’ Opinion of AARD
Many brokerage firms have already submitted their reports for AARD stocks, with RBC Capital Mkts repeating the rating for AARD by listing it as a “Outperform.” The predicted price for AARD in the upcoming period, according to RBC Capital Mkts is $21 based on the research report published on March 10, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see AARD reach a price target of $29. The rating they have provided for AARD stocks is “Overweight” according to the report published on March 10th, 2025.
Cantor Fitzgerald gave a rating of “Overweight” to AARD, setting the target price at $50 in the report published on March 10th of the current year.
AARD Trading at -5.47% from the 50-Day Moving Average
After a stumble in the market that brought AARD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.36% of loss for the given period.
Volatility was left at 13.97%, however, over the last 30 days, the volatility rate increased by 15.87%, as shares surge +9.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.17% lower at present.
During the last 5 trading sessions, AARD fell by -17.78%, in comparison to the 20-day moving average, which settled at $9.67. In addition, Aardvark Therapeutics Inc saw -38.92% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AARD starting from Decheng Capital Global Life Sc, who purchase 1,250,000 shares at the price of $16.00 back on Feb 14 ’25. After this action, Decheng Capital Global Life Sc now owns 2,958,887 shares of Aardvark Therapeutics Inc, valued at $20,000,000 using the latest closing price.
Lee Tien-Li, the Chief Executive Officer of Aardvark Therapeutics Inc, purchase 16,542 shares at $16.00 during a trade that took place back on Feb 14 ’25, which means that Lee Tien-Li is holding 1,496,175 shares at $264,672 based on the most recent closing price.
Stock Fundamentals for AARD
The total capital return value is set at -0.23.
Based on Aardvark Therapeutics Inc (AARD), the company’s capital structure generated -0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -16.48.
Currently, EBITDA for the company is -22.65 million with net debt to EBITDA at 3.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.05.
Conclusion
To put it simply, Aardvark Therapeutics Inc (AARD) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
